CSBR Champions Oncology PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: CSBR
- PE Ratio
The PE ratio for Champions Oncology stock stands at 12.6 as of May 19, 2025. This takes into account the latest EPS of $0.47 and stock price of $5.92.
CSBR PE ratio history
Over the last seven years, the average PE ratio of Champions Oncology has been 470.6. The current 12.6 P/E ratio is 97% lower than the historical average. Looking back at the last seven years, CSBR's PE ratio peaked in the Jul 2021 quarter at 1,045, with a price of $10.45 and an EPS of $0.01. The Jan 2025 quarter marked the lowest point at 23.38, with a price of $10.99 and an EPS of $0.47.
Champions Oncology PE ratio by year
Maximum annual decrease: -46.32% in 2022
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | N/A | N/A | $4.85 | -$0.54 |
| 2023 | N/A | N/A | $4.92 | -$0.39 |
| 2022 | 192 | -46.32% | $7.68 | $0.04 |
| 2021 | 357.67 | N/A | $10.73 | $0.03 |
| 2020 | N/A | N/A | $7.72 | -$0.18 |
| 2019 | 908 | N/A | $9.08 | $0.01 |
| 2018 | N/A | N/A | $4.34 | -$0.13 |
| 2017 | N/A | N/A | $2.65 | -$0.64 |
| 2016 | N/A | N/A | $3.85 | -$1.2 |
| 2015 | N/A | N/A | $7.32 | -$2.2 |
| 2014 | N/A | N/A | $10.92 | -$1.33 |
| 2013 | N/A | N/A | $5.28 | -$1.44 |
| 2012 | N/A | N/A | $8.04 | -$2.28 |
| 2011 | N/A | N/A | $12 | -$1.32 |
| 2010 | N/A | N/A | $9.24 | -$1.08 |
Champions Oncology PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Jan 2025 | 23.38 | N/A | $10.99 | $0.47 |
| Oct 2024 | N/A | N/A | $3.91 | -$0.05 |
| Jul 2024 | N/A | N/A | $4.79 | -$0.25 |
| Apr 2024 | N/A | N/A | $4.85 | -$0.54 |
| Jan 2024 | N/A | N/A | $5.81 | -$0.72 |
| Oct 2023 | N/A | N/A | $5.46 | -$0.71 |
| Jul 2023 | N/A | N/A | $6.5 | -$0.56 |
| Apr 2023 | N/A | N/A | $4.92 | -$0.39 |
| Jan 2023 | N/A | N/A | $4.11 | -$0.23 |
| Oct 2022 | 694 | 140.41% | $6.94 | $0.01 |
| Jul 2022 | 288.67 | 50.35% | $8.66 | $0.03 |
| Apr 2022 | 192 | -52.12% | $7.68 | $0.04 |
| Jan 2022 | 401 | 23.13% | $8.02 | $0.02 |
| Oct 2021 | 325.67 | -68.84% | $9.77 | $0.03 |
| Jul 2021 | 1,045 | 192.17% | $10.45 | $0.01 |
CSBR Price vs fair value
CSBR average PE ratio chart
CSBR's current PE ratio is lower than its 5 and 10-year averages.
CSBR PE vs peers
In comparison to its peer stock EXEL, CSBR's PE ratio is lower.
| Stock name | PE ratio | Market cap |
|---|---|---|
| CSBR Champions Oncology Inc | 12.6 | $81.86M |
| EXEL Exelixis Inc | 19.86 | $12.19B |
| CRL Charles River Laboratories International Inc | N/A | $6.94B |
| CLDX Celldex Therapeutics Inc | N/A | $1.39B |
Frequently asked questions
What is Champions Oncology's PE ratio?
The price to earnings ratio for CSBR stock is 12.6 as of May 19, 2025.
What is the 5-year average PE ratio for Champions Oncology (CSBR)?
The 5-year average price to earnings ratio for CSBR stock is 415.92.
What is the highest PE ratio for CSBR?
The highest quarterly PE ratio in the last seven years has been 1,045 and it was in the Jul 2021 quarter.
How does the current PE ratio for CSBR compare to its historical average?
CSBR's price to earnings ratio is currently 97% below its 7-year historical average.
How is CSBR's PE ratio calculated (Champions Oncology PE ratio formula)?
The P/E ratio is obtained by dividing the latest price of a stock by its trailing twelve months EPS. As of today (May 19, 2025), Champions Oncology's share price is $5.92. The company's earnings per share for the trailing twelve months (TTM) ending Jan 2025 is $0.47. Therefore, Champions Oncology's PE ratio for today is 12.6. PE RATIO(12.6) = STOCK PRICE($5.92) / TTM EPS($0.47)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.